Medically induced gingival hyperplasia

Mayo Clinic Proceedings

Volumn 73, Issue 12, 1998, Pages 1196-1199

  Stephen, J ^a   Meraw, D D S ^a   Phillip, J ^a   Sheridan, D D S ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN; DILTIAZEM; FELODIPINE; NITRENDIPINE; PHENYTOIN; SUCCINIMIDE DERIVATIVE; VALPROIC ACID;

DENTISTRY; ESTHETICS; GINGIVA HYPERPLASIA; GINGIVITIS; HUMAN; MASTICATION; MOUTH HYGIENE; REVIEW; SPEECH; TOOTH ERUPTION;

EID: 0031774567     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/73.12.1196     Document Type: Review

References (42)

1. Kimball OP. The treatment of epilepsy with sodium diphenyl hydantoinate. JAMA 1939;112:1244-1250
2. Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937:85:525-526
3. Jones JE, Weddell JA, McKown CG. Incidence and indications for surgical management of phenytoin-induced gingival overgrowth in a cerebral palsy population. J Oral Maxillofac Surg 1988;46:385390
4. Pihlstrom BL Prevention and treatment of Dilantin-associated gingival enlargement. Compendium 1990;ll(Suppl 14):S506-S510
5. Rose IF. Sex hormonal imbalances, oral manifestations, and dental treatment. In: Genco RJ, Goldman HM, Cohen DW, editors. Contemporary Periodontics. St. Louis: Mosby; 1990. pp 221-227
6. Rees TD, Levlne RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compendium 1995;16:20; 22; 26
7. Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol 1993;76:543-548
8. Dahllof G, Preber H, Eliasson S, Ryden H, Karsten J, Modeer T. Periodontal condition of epileptic adults treated long-term with phenytoin or carbamazepine. Epilepsia 1993;34:960-964
9. Butler RT, Kalkwarf KL, Kaldahl WB. Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. JAmDentAssoc 1987;114:56-60
10. Dahllof G, Modeer T. The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth: a 2-year longitudinal study. J Clin Periodontol 1986;13:845-849
11. Penarrocha-Diago M, Bagan-Sebastlan JV, Vera-Sempere F. Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. J Periodontol 1990;61:571-574
12. Angelopoulos AP. Diphenylhydantoin gingival hyperplasia: a clinicopathological review. I. Incidence, clinical features and histopathology. J Can Dent Assoc 1975;41:103-106
13. Macovlak JA, Oyer PE, Stinson EB, Jamieson SW, Baldwin JC, Shumway NE. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985;17(Suppl 2):97101
14. Wondimu B, Dahllof G, Berg U, Modeer T. Cyclosporin-A-induced gingival overgrowth in renal transplant children. Scand J Dent Res 1993:101:282-286
15. Allman SD, McWhorter AG, Seale NS. Evaluation of cyclosporininduced gingival overgrowth in the pédiatrie transplant patient. Pediatr Dent 1994:16:36-40
16. Seymour RA, Jacobs DJ. Cyclosporin and the gingival tissues. J Clin Periodontol 1992;19:1-11
17. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporin on some gingival health parameters of renal transplant patients: a longitudinal study. J Clin Periodontol 1987:14:610-613
18. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients: a longitudinal study. J Periodontol 1994:65:671-675
19. Morlsaki I, Akiyama YM, Miyawaki YN, Mori Y. Positive correlation between blood cyclosporin A level and severity of gingival overgrowth in rats. J Periodontol 1997;68:7-11
20. McGaw T, Lam S, Coates J. Cyclosporin-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores, and cyclosporin levels in serum and saliva. Oral Surg Oral Med Oral Pathol 1987;64:293-297
21. Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol 1991;18:107-110
22. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993; 20:286-293
23. Piattelli A, Petrelli I, Fanci P. Regression following reduction of the daily drug dosage in cyclosporin A-induced gingival overgrowth in bone marrow transplant recipients. Acta Stomatol Belg 1993;90:171176
24. McGaw WT, Porter H. Cyclosporin-induced gingival overgrowth: an ultrastructural stereologic study. Oral Surg Oral Med Oral Pathol 1988;65:186-190
25. Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663-664
26. Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M, DohertyGreenberg JM. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist 1991:11:107-109
27. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-456
28. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997:68:676-678
29. Lombard! T, Fiore-Donno G, Belser U, Di Felice R. Felodipine-induced gingival hyperplasia: a clinical and histologie study. J Oral Pathol Med 1991;20:89-92
30. Brown RS, Sein P, Corlo R, Bottomley WK. Nitrendipine-induced gingival hyperplasia: first case report. Oral Surg Oral Med Oral Pathol 1990:70:593-596
31. Nishikawa S, Tada H, Hamasaki A, Kasahara S, Kido J, Nagata T, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991:62:30-35
32. Ishlda H, Kondoh T, Kataoka M, Nishikawa S, Nakagawa T, Morlsaki I, et al. Factors influencing nifedipine-induced gingival overgrowth in rats. J Periodontol 1995:66:345-350
33. Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995:66:572578
34. Bullon P, Machuca G, Martinez-Sahuqulllo A, Rios JV, Rojas J, Lacalle JR. Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 1994;21:256-259
35. Ellis JS, Seymour RA, Monkman S, Idle JR. Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. J Periodontol Res 1993:28:373-378
36. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992:19:311-314
37. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia: a histochemical and ultrastructural study. J Periodontol 1985:56:211-215
38. Dahllof G, Axio E, Modeer T. Regression of phenytoin-induced gingival overgrowth after withdraw! of medication. SwedDentJ 1991;15:139143
39. Bokenkamp A, Bohnhorst B, Bêler C, Albers N, Offner G, Brodehl J. Nifedipine aggravâtes cyclosporin A-induced gingival hyperplasia. Pediatr Nephrol 1994:8:181-185
40. Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 1997:68:645-650
41. Carranza FA Jr. Glickman 's Clinical Periodontology. 7th ed. Philadelphia: Saunders; 1990. pp 125-148
42. Hall WB. Dilantin hyperplasia: a preventable lesion? Compendium 1990;ll(Suppl 14):S502-S505